ArticleInfectious diseases and therapy2023

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).

Gustavo H Kijak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.